ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "SLE"

  • Abstract Number: 1811 • 2015 ACR/ARHP Annual Meeting

    Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus

    April Jorge1, Apinya Lertratanakul2, Julia (Jungwha) Lee3, William Pearce1, David McPherson4, Trina Thompson5, Emma Barinas-Mitchell6 and Rosalind Ramsey-Goldman1, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, IL, 3Department of Preventive Medicine, Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 4University of Texas Health Science Center, Houston, TX, 5Saint Francis University, Ebensburg, PA, 6University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Women with SLE have an increased incidence of premature cardiovascular disease (CVD). Depression is also common among SLE patients. A relationship between depression and…
  • Abstract Number: 2081 • 2015 ACR/ARHP Annual Meeting

    The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program

    Melissa T. Flores1, Roberta Horton1, Jillian A. Rose1, Stephen A. Paget2 and Michael Lockshin3, 1Social Work Programs, Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Hospital for Special Surgery, New York, NY, 3Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY

    Background/Purpose: An evaluation was conducted of a monthly hospital-based psychoeducational support group, ongoing since 1985, for people with lupus. Each 2-hour session begins with a…
  • Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting

    Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus

    Robert Clancy1, Sokha Nhek2, Jonathan Newman3, Janet Nwaukoni1, Sara Rasmussen4, Jill P. Buyon1, Maya Rubin5, Kristen Lee1 and Jeffrey Berger5, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3Medicine, New York University School of Medicine, New York, NY, 4Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 5Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease.  Enhanced platelet activation and…
  • Abstract Number: 94 • 2015 ACR/ARHP Annual Meeting

    NGS Panel for the Detection of Monogenic SLE in Children: Initial Results

    Alexandre Belot1, Gillian Rice2, Anne-Laure Mathieu1, Brigitte Bader-Meunier3, Thierry Walzer1, Tracy A. Briggs2, James O'Sullivan4, Simon Wiliams5, Michael W. Beresford6, Yanick Crow2,7 and GENIAL Investigators, UK JSLE Study Group, 1INSERM U1111, Lyon, France, 2Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 3Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, 4University of Manchester, Manchester, United Kingdom, 5University of Manchester, Manchester, France, 6Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 7Neuroinflammation, Institut Imagine, Paris, France

    Background/Purpose: Next generation sequencing (NGS) represents a revolution in the field of molecular medicine, and offers a new approach to deciphering the pathogenesis of complex…
  • Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting

    Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays

    John Conklin1, Basil Jones2, Tyler O'Malley3, Duncan Poling4, JoAnne Ligayon5, Leilani Wolover6, Ying Qu7, Claudia Ibarra8, Puja Chitkara9 and Thierry Dervieux3, 11261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 2Exagen Diagnostics, Vista, CA, 3Research and Development, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics Inc., Vista, CA, 5Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, 6Research and Development, Exagen Diagnostics, Inc., Vista, CA, 7Exagen Diagnostic Inc, Vista, CA, 8Clinical Laboratory, Exagen Diagnostics, Vista, CA, 9Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA

    Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
  • Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting

    DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus

    Paul Renauer1, Patrick Coit1, Matlock A. Jeffries2, Joan T. Merrill3, W Joseph McCune4, Kathleen Maksimowicz-McKinnon5 and Amr H. Sawalha6, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Int Med/ Rheum, University of Michigan, Ann Arbor, MI, 5Rheumatology, Henry Ford Hospital, Detroit, MI, 6Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…
  • Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting

    Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production

    Jie An1, Joshua Woodward2, Mark Minie3, YuFeng Peng4, Tomikazu Sasaki5 and Keith B. Elkon6, 1Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, 2Department of Microbiology, University of Washington, Seattle, WA, 3Department of Bioengineering, University of Washington, Seattle, WA, 4Rheumatology, University of Washington, Seattle, WA, 5Department of Chemistry, University of Washington, Seattle, WA, 6Department of Medicine & Immunology, University of Washington, Seattle, WA

    Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
  • Abstract Number: 2125 • 2015 ACR/ARHP Annual Meeting

    Rheumatic and Non-Rheumatic Autoimmune Diseases in SLE Offspring

    Julie Couture1, Sasha Bernatsky2, Susan Scott3, Christian A. Pineau2 and Evelyne Vinet2, 1McGill University Health Centre, Montreal, QC, Canada, 2Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 3Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Autoimmune diseases (AID) have familial aggregation and frequently share a common genetic predisposition. Only few small uncontrolled studies have evaluated the risk of AID…
  • Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting

    Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®

    Chaim Putterman1, D. Scott Batty2, I.R. Cohen3, Nicole Jordan4, Debbie Rybak1, Tamar Rubinstein1, Keren Jakobi5, Rachel Sorek5, Anat Reiner-Benaim5, Yakov Blumenstein5 and Pennina Safer5, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2ImmunArray Inc., Richmond, VA, 3Weizmann Institute of Science, Rehovot, Israel, 4Montefiore Medical Center, New York, NY, 5ImmunArray LTD, Rehovot, Israel

    Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…
  • Abstract Number: 146 • 2015 ACR/ARHP Annual Meeting

    Rates of Lipid Testing and Statin Prescription Filling Among U.S. Medicaid Recipients with SLE, 2007-2010

    Sarah Chen1, Michael A. Fischer2, Hongshu Guan3, Medha Barbhaiya4 and Karen H. Costenbader5, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Internal Medicine, Weill Cornell Medical College, New York, NY, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Given high cardiovascular disease (CVD) risks in SLE patients, lipid testing and statin prescription are widely advocated for those with elevated risks. We examined…
  • Abstract Number: 788 • 2015 ACR/ARHP Annual Meeting

    Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies

    Matteo Cesaroni1, Jarrat Jordan1, Jessica Schreiter1, Marc Chevrier1, Grace Wang2, Cesar Calderon3, Alexa Piantone2, Ian Gourley4, Stanley Cohen5, Scott Fretzin6, Anna Wozniacka7, Victoria P. Werth8 and Jacqueline Benson1, 1Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, 2Janssen Research and Development, Spring House, PA, 337 Derwen Dr., Janssen Research and Development, Havertown, PA, 41329 Anthony Wayne drive, Janssen Research and Development, Wayne, PA, 5Metroplex Clinical Research Center, LLC, Dallas, TX, 6Dawes Fretzin Clinical Research Group, LLCC, Indianapolis, IN, 7Medical University of Lodz, Lodz, Poland, 8Philadelphia VA Medical Center, Philadelphia, PA

    Background/Purpose: Sub-classification of Lupus Erythematosus (LE) patients is largely based on defined clinical criteria while biological factors associating with or contributing to these clinical features…
  • Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting

    Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients

    Scott Jenks1, Benjamin Barwick2 and Ignacio Sanz3, 1Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, 2Emory University, Altanta, GA, 3Medicine, Emory University, Atlanta, GA

    Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…
  • Abstract Number: 1835 • 2015 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement

    Arielle Fein1, Caroline Figgie1, Taylor Dodds2, Joshua Wright-Chisem3, Michael Parks4, Lisa Mandl5, Edwin Su6, Jane E. Salmon5,7, David J. Mayman4, Yuo-Yu Lee8, Mark P. Figgie2 and Susan M. Goodman7, 1Research, Hospital for Special Surgery, New York, NY, 2Orthopaedics, Hospital for Special Surgery, New York, NY, 3University of Illinois at Chicago College of Medicine, Chicago, IL, 4Orthopedics, Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery, New York, NY, 6Orthopedic Surgery, Hospital for Special Surgery, New York, NY, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY

    Background/Purpose: More Systemic Lupus Erythematosus (SLE) patients are undergoing total knee arthroplasty (TKA) with equivalent benefits to osteoarthritis (OA) patients. While post-surgical adverse events (AEs)…
  • Abstract Number: 2536 • 2015 ACR/ARHP Annual Meeting

    The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl

    Sancia Ferguson1, Elianna Kaplowitz2, Laura Trupin3, Edward H. Yelin4, Patricia P. Katz3,5 and Jane E. Salmon6, 1Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, 2Hospital for Special Surgery, New York, NY, 3Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 4Medicine/Rheumatology, UC San Francisco, San Francisco, CA, 5Arthritis Research Group, University of California San Francisco, San Francisco, CA, 6Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibodies (aPL) have pregnancies with higher rates of preterm labor, preeclampsia, and fetal loss than healthy…
  • Abstract Number: 3157 • 2015 ACR/ARHP Annual Meeting

    B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE

    Chungwen Wei1, Bridget Neary2, Jamie Biear3, Jennifer Barnard3,4, Michelle Petri5, Alex Rosenberg6, Jennifer H. Anolik7 and Ignacio Sanz1, 1Rheumatology, Emory University, Atlanta, GA, 2Emory University, Atlanta, GA, 3Rheumatology, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, 6University of Rochester, Rochester, NY, 7University of Rochester Medical Center, Rochester, NY

    Background/Purpose: B cell abnormalities in SLE are well-established contributors to disease pathogenesis. Perturbation of B cell homeostasis in SLE is often described separately for each…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology